Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 83.48

-1.8%

Feb 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SnowShredder who wrote (1860)	3/29/1998 7:13:00 PM
From: Miljenko Zuanic	Read Replies (2) of 4676

Thanks Where'd ... As I said, am not up to date with RZYM. This sound like RNA/DNA base sequence modification af natural ribozymes, so vector transfer is there. For more conservative chemical modification (more stable ribosymes) , vector will not be right choice, imo. Otaku: >>BTW, has anyone noted that Sturza, the biotech investment newsletter writer has shorted ISIP in his model portfolio with a target of $8/sh?<< Sturza may make fortune one day (regardless of ISIP), but not in near future. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next